Lani
10-29-2009, 01:20 AM
I can hear Sheila ask--would insurance then allow treatment with Tykerb + Herceptin
let's hope this research moves along quickly--
Clin Cancer Res. 2009 Oct 27. [Epub ahead of print]
Altered Tissue 3'-Deoxy-3'-[18F]Fluorothymidine Pharmacokinetics in Human Breast Cancer following Capecitabine Treatment Detected by Positron Emission Tomography.
Kenny LM, Contractor KB, Stebbing J, Al-Nahhas A, Palmieri C, Shousha S, Coombes RC, Aboagye EO.
Authors' Affiliations: Department of Oncology, Imperial College London, Department of Nuclear Medicine, Imperial College Healthcare NHS Trust, and Department of Histopathology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom.
PURPOSE: We showed in preclinical models that thymidylate synthase (TS) inhibition leads to redistribution of the nucleoside transporter, ENT1, to the cell membrane and hence increases tissue uptake of [(18)F]fluorothymidine (FLT). In this study, we assessed for the first time the altered pharmacokinetics of FLT in patients following administration of capecitabine, a drug whose mode of action has been reported to include TS inhibition. EXPERIMENTAL DESIGN: We analyzed 10 lesions from six patients with breast cancer by positron emission tomography before and after treatment with capecitabine. Although drug treatment did not alter tumor delivery pharmacokinetic variables (K1 and permeability product surface area) or blood flow, tumor FLT retention variables increased with drug treatment in all but one patient. RESULTS: The baseline average standardized uptake value at 60 minutes, rate constant for the net irreversible transfer of radiotracer from plasma to tumor (Ki), and unit impulse response function at 60 minutes were 11.11 x 10(-5) m(2)/mL, 4.38 x 10(-2) mL plasma/min/mL tissue, and 4.93 x 10(-2)/min, respectively. One hour after capecitabine administration, the standardized uptake value was 13.55 x 10(-5) m(2)/mL (P = 0.004), Ki 7.40 x 10(-2) mL plasma/min/mL tissue (P = 0.004), and impulse response function was 7.40 x 10(-2)/min (P = 0.002). FLT pharmacokinetics did not change in normal tissues, suggesting that the effect was largely restricted to tumors (P = 0.55). CONCLUSIONS: We have identified FLT positron emission tomography retention parameters that could be used in future early clinical studies to measure the pharmacodynamics of TS inhibitors, as well as for identifying patients who are unlikely to benefit from TS inhibition. (Clin Cancer Res 2009;15(21):6649-57).
PMID: 19861447
let's hope this research moves along quickly--
Clin Cancer Res. 2009 Oct 27. [Epub ahead of print]
Altered Tissue 3'-Deoxy-3'-[18F]Fluorothymidine Pharmacokinetics in Human Breast Cancer following Capecitabine Treatment Detected by Positron Emission Tomography.
Kenny LM, Contractor KB, Stebbing J, Al-Nahhas A, Palmieri C, Shousha S, Coombes RC, Aboagye EO.
Authors' Affiliations: Department of Oncology, Imperial College London, Department of Nuclear Medicine, Imperial College Healthcare NHS Trust, and Department of Histopathology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom.
PURPOSE: We showed in preclinical models that thymidylate synthase (TS) inhibition leads to redistribution of the nucleoside transporter, ENT1, to the cell membrane and hence increases tissue uptake of [(18)F]fluorothymidine (FLT). In this study, we assessed for the first time the altered pharmacokinetics of FLT in patients following administration of capecitabine, a drug whose mode of action has been reported to include TS inhibition. EXPERIMENTAL DESIGN: We analyzed 10 lesions from six patients with breast cancer by positron emission tomography before and after treatment with capecitabine. Although drug treatment did not alter tumor delivery pharmacokinetic variables (K1 and permeability product surface area) or blood flow, tumor FLT retention variables increased with drug treatment in all but one patient. RESULTS: The baseline average standardized uptake value at 60 minutes, rate constant for the net irreversible transfer of radiotracer from plasma to tumor (Ki), and unit impulse response function at 60 minutes were 11.11 x 10(-5) m(2)/mL, 4.38 x 10(-2) mL plasma/min/mL tissue, and 4.93 x 10(-2)/min, respectively. One hour after capecitabine administration, the standardized uptake value was 13.55 x 10(-5) m(2)/mL (P = 0.004), Ki 7.40 x 10(-2) mL plasma/min/mL tissue (P = 0.004), and impulse response function was 7.40 x 10(-2)/min (P = 0.002). FLT pharmacokinetics did not change in normal tissues, suggesting that the effect was largely restricted to tumors (P = 0.55). CONCLUSIONS: We have identified FLT positron emission tomography retention parameters that could be used in future early clinical studies to measure the pharmacodynamics of TS inhibitors, as well as for identifying patients who are unlikely to benefit from TS inhibition. (Clin Cancer Res 2009;15(21):6649-57).
PMID: 19861447